Skip to main content
Jerry Mendell, MD, Neurology, Columbus, OH, Ohio State University Wexner Medical Center

JerryRMendellMD

Neurology • Columbus, OH

Interventional Neurology, Neuromuscular Medicine, Child Neurology

Professor of Pediatrics and Neurology, Ohio State University Curran Peters Chair of Research Translational Gene Therapy Scientist

Join to view full profile

Dr. Mendell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Mendell's full profile

Already have an account?

Education & Training

  • Clinical Center at the National Institutes of Health
    Clinical Center at the National Institutes of HealthFellowship, Neuromuscular Medicine (Neurology), 1969 - 1972
  • New York Presbyterian Hospital (Columbia Campus)
    New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 1966 - 1969
  • University of Texas Southwestern Medical School
    University of Texas Southwestern Medical SchoolClass of 1966

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 1972 - 2024
  • TX State Medical License
    TX State Medical License 1966 - 1988
  • American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • Sidney Carter Award in Child Neurology American Academy of Neurology 2021
  • America's Top Doctors Castle Connolly, 2002-2022
  • Bernard Sachs Lecture Child Neurology Society, 2021
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children with Duchenne Muscular Dystrophy  
    Jerry R Mendell, Zarife Sahenk, Samiah Al-Zaidy, Richard Shell, JAMA Neurology

Authored Content

  • Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children with Duchenne Muscular DystrophyJune 2020

Press Mentions

  • MD Gene Therapy Invented at Nationwide Children's Could Hit $4B Annual Sales if Approved
    MD Gene Therapy Invented at Nationwide Children's Could Hit $4B Annual Sales if ApprovedJanuary 31st, 2023
  • Can the FDA Keep the Momentum Going for Rare Disease Drug Approvals?
    Can the FDA Keep the Momentum Going for Rare Disease Drug Approvals?January 23rd, 2023
  • A Kansas Man with a Rare Disorder Spent Decades Advocating for Gene Therapy. It May Never Help Him
    A Kansas Man with a Rare Disorder Spent Decades Advocating for Gene Therapy. It May Never Help HimMay 25th, 2022
  • Join now to see all

Grant Support

  • Vascular Delivery Of Alpha-Sarcoglycan For Lgmd2dNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
  • The Implications Of Dystrophin-Specific T Cells For DMD Gene CorrectionEunice Kennedy Shriver National Institute Of Child Health &Human Development2010–2011
  • Overcoming Immune Barriers To Gene Correction For Duchenne Muscular DystrophyEunice Kennedy Shriver National Institute Of Child Health &Human Development2010–2011
  • Administrative CoreEunice Kennedy Shriver National Institute Of Child Health &Human Development2010–2011
  • Dystrophin RestorationNational Institute Of Neurological Disorders And Stroke2007–2010
  • Diverse Strategies To Correct The Dystrophin Gene Using Vascular Delivery (U54)National Institute Of Neurological Disorders And Stroke2007–2010
  • Implementing Newborn Screening For Duchenne Muscular Dystrophy In The CommunityCenters For Disease Control And Prevention2007–2009
  • Clinical Trial: Six-Month (26 Weeks) Clinical Trial Of Gentamicin In Duchenne MDNational Center For Research Resources2008
  • Developing Clinical Outcomes For Gene TransferNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2003–2008
  • Administrative CoreNational Institute Of Neurological Disorders And Stroke2007
  • Study Of SR 57746a In Patients With Amyotrophic Lateral SclerosisNational Center For Research Resources2007
  • Study Of MYO-029National Center For Research Resources2007
  • Six-Month (26 Weeks) Clinical Trial Of Gentamicin In Duchenne MDNational Center For Research Resources2006–2007
  • Newborn Screening For Duchenne Muscular DystrophyCenters For Disease Control And Prevention2004–2007
  • Gentamicin Trial In Duchenne And Limb Girdle DystrophiesNational Institute Of Neurological Disorders And Stroke2004
  • Gentamicin Trial In Duchenne And Limb Girdle DystrophiesNational Institute Of Neurological Disorders And Stroke2002–2003
  • LGMD Study GroupNational Center For Research Resources1999–2001
  • Great Lakes ALS Study GroupNational Center For Research Resources1999–2001
  • Efficacy, Safety, Tolerability Of Sr57746a In ALS PatientsNational Center For Research Resources1999–2001
  • Efficacy Of Sr57746a In Patients With Amyotrophic Lateral SclerosisNational Center For Research Resources1998–2001
  • Clinical Trial Of Oxandrin In Treatment Of Duchennes Muscular DystrophyNational Center For Research Resources1998–2001
  • Intravenous Immunoglobulin In CipdNational Center For Research Resources1996–2001
  • Treatment Of Patients With Amyotrophic Lateral Sclerosis Using A Ketogenic DietNational Center For Research Resources2000
  • Safety, Efficacy And Tolerability Of Beta Interferon1a In Inclusion Body MyositisNational Center For Research Resources2000
  • Multicenter Trial In Periodic Paralysis And Sodium Channel DisorderNational Center For Research Resources1997
  • Androgen Hormone Deficiency And Replacement In Motor Neuron DiseaseNational Center For Research Resources1996–1997
  • Myoblast Transfer Studies In Duchenne Muscular DystrophyNational Center For Research Resources1996
  • Multicenter Trial In Periodic Paralysis &Associated Sodium Channel DisorderNational Center For Research Resources1996

Hospital Affiliations

Dr. Jerry Mendell, Dr. Jerry Mendell, MD, Dr. J Mendell, Dr. Jerry R Mendell